Antibodies global markets worth in excess of US$100bn29 Jan 2020 11:51
Highly encouraging results for Avacta’s TMAC programme. The Group’s first TMACTMdrug conjugate molecule has demonstrated ability to out-perform Bavencio(avelumab)in an animal model.In vivoand pharmacokinetic data collected indicatesuperior efficacy which,together with ability to successfully target thewarhead,providesinitial proof-of-concept. As such,today’s newsrepresents the passing of a keymilestone with thevery first TMAC tested. Given a peak sales projection of US$4bn/yearfor Bavencio,significant commercial interest that Avacta’sdevelopment programme has already attracted mightnow multiply still further.
The Affimer platform is an alternative to antibodies derived from a small human protein.Despite their obvious shortcomings, antibodies currently dominate global markets worth in excess of US$100bn. Success in signingresearch and development accords with three majorinternational companies, in the formof a partnership, collaboration anda joint venture, represents not only a major endorsement of Avacta’s technology, but also highlightsBig Pharma’s determinationto invest in such giant, albeit early-stage,opportunities.Meanwhile,through combination of its two proprietary platforms(Affimer® biotherapeutics and pre|CISION™), Avactais building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Today’s news potentially kicks-offaground-breaking year,withthe Group proposing to take its first drug, AVA6000, a pre|CISIONtargeted form of the standard-of-care Doxorubicin, into the clinic duringthe second half of 2020.Designed to reduce side effects without affecting efficacy, the molecule’s initial readouts are expected before the end of thisyear and potentially representa major inflection point along with anopportunity for creation of significant commercial value, while the Group also forwardsits partnered programmes and licensing relationships for its diagnostics reagents
Sign In
Follow the stocks
